Comparison of a gene expression profiling strategy to standard clinical work-up for determination of tumour origin in cancer of unknown primary (CUP)

References

• FizaziKGrecoFAPavlidisNPentheroudakisG. Cancers of unknown primary site: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2011;22 Suppl 6:vi64–8.
   PubMed Web of Science ®Google Scholar
• PavlidisNFizaziK. Carcinoma of unknown primary (CUP). Crit Rev Oncol Hematol. 2009;69(3):271–8.
   PubMed Web of Science ®Google Scholar
• Identifying the primary site using gene expression profiling in patients with carcinoma of an unknown primary (CUP): a feasibility study from the GEFCAPI. ASCO [Internet]. [cited 2011 Oct 19]. Available from: http://www.asco.org/ascov2/Meetings/Abstracts?&vmview = abst_detail_view&confID = 65&abstractID = 34102
   Google Scholar
• occult.pdf [Internet]. [cited 2011 Oct 25]. Available from: http://www.nccn.org/professionals/physician_gls/PDF/occult.pdf
   Google Scholar
• SchapiraDVJarrettAR. The need to consider survival, outcome, and expense when evaluating and treating patients with unknown primary carcinoma. Arch Intern Med. 1995;155(19):2050–4.
   PubMedGoogle Scholar
• Le ChevalierTCvitkovicECaillePHarveyJContessoGSpielmannM. Early metastatic cancer of unknown primary origin at presentation. A clinical study of 302 consecutive autopsied patients. Arch Intern Med. 1988;148(9):2035–9.
   PubMedGoogle Scholar
• AbbruzzeseJLAbbruzzeseMCLenziRHessKRRaberMN. Analysis of a diagnostic strategy for patients with suspected tumors of unknown origin. J Clin Oncol. 1995;13(8):2094–103.
   PubMed Web of Science ®Google Scholar
• KweeTCKweeRM. Combined FDG-PET/CT for the detection of unknown primary tumors: systematic review and meta-analysis. Eur Radiol. 2009;19(3):731–44.
   PubMed Web of Science ®Google Scholar
• DumurCILyons-WeilerMSciulliCGarrettCTSchrijverIHolleyTK. Interlaboratory performance of a microarray-based gene expression test to determine tissue of origin in poorly differentiated and undifferentiated cancers. J Mol Diagn. 2008;10(1):67–77.
   PubMed Web of Science ®Google Scholar
• DennisJLHvidstenTRWitECKomorowskiJBellAKDownieI. Markers of adenocarcinoma characteristic of the site of origin: development of a diagnostic algorithm. Clin Cancer Res. 2005;11(10):3766–72.
   PubMed Web of Science ®Google Scholar
• TothillRWKowalczykARischinDBousioutasAHavivIVan LaarRK. An expression-based site of origin diagnostic method designed for clinical application to cancer of unknown origin. Cancer Res. 2005;65(10):4031–40.
   PubMed Web of Science ®Google Scholar
• Van LaarRKMaX-JDe JongDWehkampDFlooreANWarmoesMO. Implementation of a novel microarray-based diagnostic test for cancer of unknown primary. Int J Cancer. 2009;125(6):1390–7.
   PubMed Web of Science ®Google Scholar
• BridgewaterJVan LaarRFlooreAVan’T VeerL. Gene expression profiling may improve diagnosis in patients with carcinoma of unknown primary. Br J Cancer. 2008;98(8):1425–30.
   PubMed Web of Science ®Google Scholar
• HorlingsHMVan LaarRKKerstJ-MHelgasonHHWesselingJVan der HoevenJJM. Gene expression profiling to identify the histogenetic origin of metastatic adenocarcinomas of unknown primary. J Clin Oncol. 2008;26(27):4435–41.
   PubMed Web of Science ®Google Scholar
• MorawietzLFlooreAStork-SlootsLFolprechtGBuettnerRRiegerA. Comparison of histopathological and gene expression-based typing of cancer of unknown primary. Virchows Arch. 2010;456(1):23–9.
   PubMed Web of Science ®Google Scholar
• MaX-JPatelRWangXSalungaRMurageJDesaiR. Molecular classification of human cancers using a 92-gene real-time quantitative polymerase chain reaction assay. Arch Pathol Lab Med. 2006;130(4):465–73.
   PubMed Web of Science ®Google Scholar
• CentenoBABloomGChenD-TChenZGruidlMNasirA. Hybrid model integrating immunohistochemistry and expression profiling for the classification of carcinomas of unknown primary site. J Mol Diagn. 2010;12(4):476–86.
   PubMed Web of Science ®Google Scholar
• DennisJLHvidstenTRWitECKomorowskiJBellAKDownieI. Markers of adenocarcinoma characteristic of the site of origin: development of a diagnostic algorithm. Clin Cancer Res. 2005;11(10):3766–72.
   PubMed Web of Science ®Google Scholar
• TalantovDBadenJJatkoeTHahnKYuJRajpurohitY. A quantitative reverse transcriptase-polymerase chain reaction assay to identify metastatic carcinoma tissue of origin. J Mol Diagn. 2006;8(3):320–9.
   PubMed Web of Science ®Google Scholar
• SuAIWelshJBSapinosoLMKernSGDimitrovPLappH. Molecular classification of human carcinomas by use of gene expression signatures. Cancer Res. 2001;61(20):7388–93.
   PubMed Web of Science ®Google Scholar
• VaradhacharyGRTalantovDRaberMNMengCHessKRJatkoeT. Molecular profiling of carcinoma of unknown primary and correlation with clinical evaluation. J Clin Oncol. 2008;26(27):4442–8.
   PubMed Web of Science ®Google Scholar
• MonzonFAMedeirosFLyons-WeilerMHennerWD. Identification of tissue of origin in carcinoma of unknown primary with a microarray-based gene expression test. Diagn Pathol. 2010;5:3.
   PubMed Web of Science ®Google Scholar
• GrecoFARodriguezGIShafferDWHermannRLitchySYardleyDA. Carcinoma of unknown primary site: sequential treatment with paclitaxel/carboplatin/etoposide and gemcitabine/irinotecan: a Minnie Pearl Cancer Research Network phase II trial. Oncologist. 2004;9(6):644–52.
   PubMed Web of Science ®Google Scholar
• ErlanderMGMaX-JKestyNCBaoLSalungaRSchnabelCA. Performance and clinical evaluation of the 92-gene real-time PCR assay for tumor classification. J Mol Diagn. 2011;13(5):493–503.
   PubMed Web of Science ®Google Scholar
• KerrSESchnabelCASullivanPSZhangYSinghVCareyB. Multisite validation study to determine performance characteristics of a 92-gene molecular cancer classifier. Clin Cancer Res. 2012;18(14):3952–60.
   PubMed Web of Science ®Google Scholar
• GrecoFASpigelDRYardleyDAErlanderMGMaX-JHainsworthJD. Molecular profiling in unknown primary cancer: accuracy of tissue of origin prediction. Oncologist. 2010;15(5):500–6.
   PubMed Web of Science ®Google Scholar
• HainsworthJDRubinMSSpigelDRBocciaRVRabySQuinnR. Molecular gene expression profiling to predict the tissue of origin and direct site-specific therapy in patients with carcinoma of unknown primary site: a prospective trial of the Sarah Cannon Research Institute. JCO. 2013;31(2):217–23.
   PubMed Web of Science ®Google Scholar
• MichielsSKramarAKoscielnyS. Multidimensionality of microarrays: statistical challenges and (im)possible solutions. Mol Oncol. 2011;5(2):190–6.
   PubMed Web of Science ®Google Scholar
• Genetic testing or clinical assessment in determining the need for chemotherapy in women with breast cancer that involves no more than 3 lymph nodes. Full Text View. ClinicalTrials.gov [Internet]. [cited 2011 Nov 29]. Available from: http://clinicaltrials.gov/ct2/show/NCT00433589?term = mindact&rank = 1
   Google Scholar
• Hormone therapy with or without combination chemotherapy in treating women who have undergone surgery for node-negative breast cancer (The TAILORx Trial). Full Text View. ClinicalTrials.gov [Internet]. [cited 2011 Nov 29]. Available from: http://clinicaltrials.gov/ct2/show/NCT00310180?term = tailorX&rank = 1
   Google Scholar
• HaasIHoffmannTKEngersRGanzerU. Diagnostic strategies in cervical carcinoma of an unknown primary (CUP). Eur Arch Otorhinolaryngol. 2002;259(6):325–33.
   PubMed Web of Science ®Google Scholar
• Von HoffDDStephensonJJJrRosenPLoeschDMBoradMJAnthonyS. Pilot study using molecular profiling of patients’ tumors to find potential targets and select treatments for their refractory cancers. J Clin Oncol. 2010;28(33):4877–83.
   PubMed Web of Science ®Google Scholar